Analyst Andrew Peters is focused on the Healthcare sector with 130 price targets and ratings documented since 2010 spanning on 8 stocks. Previously, Andrew Peters worked at DEUTSCHE BANK, UBS. Analyst's average stock valuation to be materialised ratio is 87.03% with an average time for price targets to be met of 411.75 days.
Most recent stock forecast was given on ESPR, Esperion Therapeutics, Inc at 03-May-2018.
Andrew Peters best performing recommendations are on HALO (HALOZYME THERAPEUTICS, INC).
The best stock recommendation documented was for HALO (HALOZYME THERAPEUTICS, INC) at 11/3/2016. The price target of $12 was fulfilled within 7 days with a profit of $3.54 (41.84%) receiving and performance score of 59.78.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
130
$17.8 (15.86%)
122
3 days ago
17/25 (68%)
$34.75 (43.23%)
883
Buy
132
$19.8 (17.65%)
113
13 days ago
19/21 (90.48%)
$14.43 (16.25%)
353
Hold
83
$-29.2 (-26.02%)
70
26 days ago
0/2 (0%)
$-15.03 (-14.00%)
Buy
120
$7.8 (6.95%)
100
2 months 8 days ago
3/4 (75%)
$21.09 (25.40%)
338
Buy
133
$20.8 (18.54%)
133
2 months 12 days ago
5/13 (38.46%)
$32.57 (39.12%)
273
